Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 19.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000044 | James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000190 | Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] ; Renato P. Munhoz [Brésil] ; Katia Charland [Canada] ; Amelie Pelletier [Canada] ; Mariana Moscovich [Brésil] ; Luciane Filla [Brésil] ; Debora Zanatta [Brésil] ; Silvia Rios Romenets [Canada] ; Robert Altman [Canada] ; Rosa Chuang [Canada] ; Binit Shah [Canada] | Caffeine for treatment of Parkinson disease: A randomized controlled trial |
| 000235 | Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada] | Predictors of Time to Requiring Dopaminergic Treatment in 2 Parkinson's Disease Cohorts |
| 000340 | Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [États-Unis] | Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study |
| 000402 | Anthony E. Lang [Canada] | When and how should treatment be started in Parkinson disease? |
| 000499 | Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
| 000592 | Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 000612 | Janis M. Miyasaki [Canada] ; Khalid Al Hassan [Canada] ; Anthony E. Lang [Canada] ; Valerie Voon [Canada] | Punding prevalence in Parkinson's disease |
| 000675 | Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 000683 | Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 000744 | Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis] | Crossroads in GDNF therapy for Parkinson's disease |
| 000854 | Ajmal Razmy [Canada] ; Anthony E. Lang [Canada] ; Colin M. Shapiro [Canada] | Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists |
| 000874 | Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] | Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? |
| 000945 | Galit Kleiner-Fisman [Canada] ; David N. Fisman ; Elspeth Sime ; Jean A. Saint-Cyr ; Andres M. Lozano ; Anthony E. Lang | Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease |
| 000984 | Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000A33 | Anthony E. Lang [Canada] ; Hakan Widner [Suède] | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation |
| 000A69 | Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] | Pallidotomy for Parkinson's disease |
| 000A84 | Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
| 000B36 | Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| This area was generated with Dilib version V0.6.29. |  |